In vivo measurement of fluorescence emission in the human prostate during photodynamic therapy

Among the challenges to the clinical implementation of photodynamic therapy (PDT) is the delivery of a uniform photodynamic dose to induce uniform damage to the target tissue. As the photodynamic dose depends on both the local sensitizer concentration and the local fluence rate of treatment light, knowledge of both of these factors is essential to the delivery of uniform dose. In this paper, we investigate the distribution and kinetics of the photosensitizer motexafin lutetium (MLu, Lutrin) as revealed by its fluorescence emission. Our current prostate treatment protocol involves interstitial illumination of the organ via cylindrical diffusing fibers (CDF’s) inserted into the prostate though clear catheters. For planning and treatment purposes, the prostate is divided into 4 quadrants. We use one catheter in each quadrant to place an optical fiber-based fluorescence probe into the prostate. This fiber is terminated in a beveled tip, allowing it to deliver and collect light perpendicular to the fiber axis. Excitation light is provided by a 465 nm light emitting diode (LED) source coupled to a dichroic beamsplitter, which passes the collected fluorescence emission to a CCD spectrograph. Spectra are obtained before and after PDT treatment in each quadrant of the prostate and are analyzed via a linear fitting algorithm to separate the MLu fluorescence from the background fluorescence originating in the plastic catheter. A computer-controlled step motor allows the excitation/detection fiber to be moved along the catheter, building up a linear profile of the fluorescence emission spectrum of the tissue as a function of position. We have analyzed spectral fluorescence profiles obtained in 4 patients before and after MLu-mediated PDT. We find significant variation both within individual prostates and among patients. Within a single quadrant, we have observed the fluorescence signal to change by as much as a factor of 3 over a distance of 2 cm. Comparisons of pre- and post-PDT spectra allow a quantification treatment-induced photobleaching. Like the drug distribution, the extent of photobleaching varies widely among patients. In two cases, we observed bleaching of approximately 50% of the drug, while others exhibited negligible photobleaching.

[1]  M Saunders,et al.  Photodynamic therapy in the canine prostate using motexafin lutetium. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  R. Rava,et al.  Analytical model for extracting intrinsic fluorescence in turbid media. , 1993, Applied optics.

[3]  Timothy C. Zhu,et al.  Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer , 2004, SPIE BiOS.

[4]  E. Hull,et al.  Porphyrin Bleaching and PDT-induced Spectral Changes are Irradiance Dependent in ALA-sensitized Normal Rat Skin In Vivo¶ , 2001, Photochemistry and photobiology.

[5]  Andreea Dimofte,et al.  Optical Properties of Human Prostate at 732 nm Measured In Vivo During Motexafin Lutetium–mediated Photodynamic Therapy ¶ , 2005 .

[6]  J. Sessler,et al.  Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer , 1996, Photochemistry and photobiology.

[7]  Timothy C. Zhu,et al.  Optical Properties of Human Prostate at 732 nm Measured In Vivo During Motexafin Lutetium–mediated Photodynamic Therapy¶ , 2005 .

[8]  Jonathan L. Sessler,et al.  Texaphyrins: Synthesis and Development of a Novel Class of Therapeutic Agents , 2002 .

[9]  Thomas S. Mang,et al.  THE THEORY OF PHOTODYNAMIC THERAPY DOSIMETRY: CONSEQUENCES OF PHOTO‐DESTRUCTION OF SENSITIZER , 1987 .

[10]  B. Wilson,et al.  Forward-adjoint fluorescence model: Monte Carlo integration and experimental validation. , 1997, Applied optics.

[11]  Jarod C Finlay,et al.  Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. , 2005, Journal of photochemistry and photobiology. B, Biology.

[12]  Michael S Patterson,et al.  Quantification of fluorophore concentration in tissue-simulating media by fluorescence measurements with a single optical fiber. , 2003, Applied optics.

[13]  T. Foster,et al.  Singlet Oxygen‐Versus Nonsinglet Oxygen‐Mediated Mechanisms of Sensitizer Photobleaching and Their Effects on Photodynamic Dosimetry , 1998, Photochemistry and photobiology.

[14]  S L Jacques,et al.  Fluorescence spectroscopy of tissue: recovery of intrinsic fluorescence from measured fluorescence. , 1996, Applied optics.

[15]  Jarod C Finlay,et al.  In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy , 2004, SPIE BiOS.

[16]  M S Patterson,et al.  Noninvasive measurement of fluorophore concentration in turbid media with a simple fluorescence /reflectance ratio technique. , 2001, Applied optics.

[17]  J Wu,et al.  Intrinsic fluorescence spectroscopy in turbid media: disentangling effects of scattering and absorption. , 2001, Applied optics.

[18]  R R Alfano,et al.  Correction of the internal absorption effect in fluorescence emission and excitation spectra from absorbing and highly scattering media: theory and experiment. , 1998, Journal of biomedical optics.

[19]  Anthony J. Durkin,et al.  Relation between fluorescence spectra of dilute and turbid samples. , 1994, Applied optics.

[20]  B. Wilson,et al.  A diffusion theory model of spatially resolved, steady-state diffuse reflectance for the noninvasive determination of tissue optical properties in vivo. , 1992, Medical physics.

[21]  Jarod C Finlay,et al.  Recovery of hemoglobin oxygen saturation and intrinsic fluorescence with a forward-adjoint model. , 2005, Applied optics.